Neuland Laboratories shares rose sharply on Thursday after the drugmaker reported a 975% year-on-year surge in Q1 FY27 profit to Rs 147.4 crore. Revenue more than doubled, while EBITDA jumped 448%, driven by strong commercial product sales and encouraging performance across its CMS and GDS businesses.
Global Market: DBS raises full-year outlook as record Q2 profit beats estimates
DBS Group announced a robust nine percent increase in net profit for the second quarter, bolstered by a remarkable forty-two percent rise in wealth management